BioSpace News Archive

Drug Development

Antengene to Present Preclinical Data Demonstrating the Synergistic Effect of the Combination of XPO1 and mTORC1/2 Inhibition for the Treatment of Triple-Hit DLBCL at AACR Annual Meeting 2021

Antengene Corporation Limited announced that it will present the preclinical data on the synergistic effect of the combination of XPO1 and mTORC1/2 inhibition for the treatment of triple-hit diffuse large B-cell lymphoma at the American Association for Cancer Research Annual Meeting 2021, which will be held in a virtual format on April 10-15 and May 17-21, 2021.

March 21, 2021
·
4 min read
Policy

Statement from the Chief Public Health Officer of Canada on March 21, 2021

The COVID-19 pandemic continues to create stress and anxiety for many Canadians, particularly those who do not have ready access to their regular support networks.

March 21, 2021
·
7 min read
Drug Development

Harbour BioMed Announces Dosing of First Patient in Phase I Clinical Study of its Next-Generation Anti-CTLA-4 Antibody in China

Harbour BioMed announced the dosing of the first patient in its open Phase I clinical study of HBM4003 for Chinese patients suffering from advanced melanoma and other solid tumors.

March 21, 2021
·
3 min read